Physician profile
Hassan R Mir
NPI 1467675710
$877,325.77
in general payments reported to CMS, 2019-2025
22 companies · $228K in 2025
The $228K reported for 2025 was more than what 98% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $38K · 2021: $39K · 2022: $92K · 2023: $109K · 2024: $290K · 2025: $228K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $213K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Acquisitions: $157K · Travel and Lodging: $50K · Food and Beverage: $9,297 · Honoraria: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $212,857.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $195,975.00 |
| Acquisitions | $157,138.43 |
| Travel and Lodging | $50,440.41 |
| Food and Beverage | $9,297.08 |
| Honoraria | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $410,574.43 | 2019-2025 | Evos, Evos Mini, Trigen |
| Zimmer Biomet Holdings, INC. | $192,162.00 | 2019-2024 | |
| Stryker Corporation | $104,194.70 | 2019-2025 | Pangea, Hoffmann, Axsos |
| Acumed LLC | $62,953.35 | 2022-2025 | Acumed, Osteomed, Acumed |
| Pharmaceutical Business Consultants Limited | $50,827.29 | 2022-2025 | |
| Medical Device Business Services, INC. | $32,419.70 | 2021-2025 | Va-Lcp, Hammerlock |
| Trackx Technology, INC. | $7,873.81 | 2023 | |
| Ge Healthcare | $6,804.79 | 2025 | |
| Si-Bone, INC. | $5,928.81 | 2024-2025 | |
| Biomimetic Innovations Limited | $1,500.00 | 2022-2023 | |
| Globus Medical, INC. | $578.00 | 2023 | Ankle Fracture System, Excelsiusgps Robotic Navigation System, Proximal Tibia Plate |
| Polynovo North America LLC | $573.63 | 2024-2025 | Novosorb Btm |
| Synthes Gmbh | $500.00 | 2020 | |
| US Implant Solutions, LLC | $118.51 | 2023 | |
| Sanara Medtech INC. | $96.09 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $57.94 | 2023 | Restrata Wound Matrix |
| Depuy Synthes Sales INC. | $48.42 | 2023 | Na |
| Next Science LLC | $42.71 | 2022 | |
| Ethicon US, LLC | $36.03 | 2023 | Dermabond Prineo |
| Acell, INC. | $23.48 | 2019 | |
| Brainlab, INC. | $12.08 | 2023 | Image Guided Surgical Device |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,059.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.